Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Phathom Pharmaceuticals (PHAT) Receivables - Net (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Receivables - Net for 3 consecutive years, with $78.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 101.38% to $78.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.1 million, a 101.38% increase, with the full-year FY2025 number at $78.1 million, up 101.38% from a year prior.
  • Receivables - Net was $78.1 million for Q4 2025 at Phathom Pharmaceuticals, up from $55.8 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $78.1 million in Q4 2025 to a low of $1.6 million in Q4 2023.
  • A 3-year average of $33.1 million and a median of $36.4 million in 2025 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: soared 2270.01% in 2024, then surged 101.38% in 2025.
  • Phathom Pharmaceuticals' Receivables - Net stood at $1.6 million in 2023, then skyrocketed by 2270.01% to $38.8 million in 2024, then soared by 101.38% to $78.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Receivables - Net are $78.1 million (Q4 2025), $55.8 million (Q3 2025), and $51.3 million (Q2 2025).